Metadata supporting the article: Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes
Creators: name: Gardner, Kirby P.
name: Aldakkak, Mohammed
name: Cha-Mei Tang
name: Tsai, Susan
name: Adams, Daniel L.
Publisher: name: figshare
Year: 2021
Subjects: subject: 111201 Cancer Cell Biology
subject: FOS: Clinical medicine
subject: FOS: Clinical medicine
subject: Cancer
subject: 111202 Cancer Diagnosis
subject: Biological Techniques
subject: 69999 Biological Sciences not elsewhere classified
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Biomarkers
subject: Medicine

description: Pancreatic cancer (PC) is notoriously difficult to diagnosis and properly stage resulting in incorrect primary treatment. Diagnostic and prognostic biomarkers are desperately needed to more accurately stage patients and select proper treatments. Recently, a newly discovered circulating stromal cell, i.e. cancer associated macrophage-like cell (CAML), was found to accurately identify solid cancers and predict for worse prognosis. To date, no study has evaluated the clinical utility of CAML numbers or CAML size specifically in PC patients. In this study, 63 PC patients who were candidates for surgical resection were asked to volunteer a blood sample for CAML and Circulating Tumor Cells (CTC) analysis. Patients were tracked through standard of care neoadjuvant therapy and surgical resection (if surgery was completed), monitored for 24 months to determine the clinical utility of CAML number or CAML size in progression free survival (PFS) or overall survival (OS).<br> <b>Data access:</b> The data generated and analysed during this study (Gardner Repository.xlsx), are publicly available in the figshare repository: <b>https://doi.org/10.6084/m9.figshare.13660916</b>. The original cell images supporting figure 1, will be made available on reasonable request from Dr. Kirby Gardner, email address: <b>kgardner@creatvmicrotech.com</b>.<br> <b>Study approval and patient consent</b>: Peripheral blood samples were obtained from 63 PC patients through collaboration with the Medical College of Wisconsin, in accordance with the local institutional review board (IRB) approval and with the patient’s informed consent. Blood samples from 40 age matched healthy control volunteers, were collected according to local IRB (Western Institutional Review Board) approval and with informed consent.<br> <b>Study aims and methodology</b>: (CAMLs) cells are a recently identified blood based biomarker found in cancer patients which appear to provide clinical utility in a variety of solid tumor types (i.e. breast, prostate, and lung). This study aimed to analyse the clinical utility of CAMLs in pancreatic cancer, using both pre-treated and treatment naïve patient samples in all stages of disease. Blood samples were procured from 63 PC patients prior to start of therapeutic intent. In addition, blood samples from 40 age matched healthy control volunteers, including 16 females (40%) and 24 males (60%) with an average age of 64.4 years old, were collected in CellSave tubes. The following are described in more detail in the related article: tumor associated circulating cell capture, analysis of filters, and statistical analysis. <br> <b>Data supporting the related article:</b> Data supporting figure 1: Original cell images are in .eps file format. Data supporting figure 2: <b>Gardner Repository.xlsx</b>, in .xlsx file format (Main Data Baseline tab). Data supporting figure 3: Gardner Repository.xlsx, in .xlsx file format (Figure 2a tab). Data supporting figure 4: Gardner Repository.xlsx, in .xlsx file format (Main Data Baseline tab). Data supporting figure 5: Gardner Repository.xlsx, in .xlsx file format (Fig 5 and Sup Fig 6 tab). Data supporting table 1 and supplementary tables 1-7: Gardner Repository.xlsx, in .xlsx file format (Main Data Baseline tab).